An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Immunome to Present at the Stifel 2023 Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
IMNM: Immunome to Present at Stifel 2023 Healthcare Conference, CEO Clay Siegall to Speak on Targeted Cancer Therapies
Positive
Immunome's participation in the Stifel 2023 Healthcare Conference indicates industry recognition and potential networking opportunities for the company and its CEO.
The focus on developing first-in-class and best-in-class targeted cancer therapies demonstrates Immunome's commitment to innovation and addressing unmet medical needs in the oncology space.
Negative
None.
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
What is the latest announcement from Immunome, Inc. (IMNM)?
Immunome, Inc. (IMNM) announced that its President and CEO, Clay Siegall, PhD, will present at the Stifel 2023 Healthcare Conference to discuss targeted cancer therapies.
When and where will the presentation take place?
The presentation will be held on Wednesday, November 15, at 3:00 p.m. ET, and interested parties can access the live audio webcast from the Investor Relations section of Immunome's website at www.immunome.com.
How long will the webcast be available for replay?
The webcast replay will be accessible for approximately 90 days after the conclusion of the live presentation.
immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. this proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. we then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.
